Skip to main content

Advertisement

Fig. 1 | Breast Cancer Research

Fig. 1

From: The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer

Fig. 1

a Disease-free survival by continuous risk of recurrence (ROR) score 0–5 years and 5–10 years after randomization, respectively, for patients in the systemically untreated regimen (CT –) and patients in the C/CMF arm (CT +). b Overall survival by continuous ROR score for 0–5 years and 5+ years after randomization, respectively. Hazard ratios and corresponding 95% CI for a 10-point difference in continuous ROR score are shown

Back to article page